FPS
CTIC

Fieldpoint Private Securities’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Fieldpoint Private Securities’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$3K – 1775
2021
Q3 		$3K Hold
1,000
– – ﹤0.01% 1429
2021
Q2 		$3K Hold
1,000
– – ﹤0.01% 1357
2021
Q1 		$3K Buy
+1,000
New +$3.26K ﹤0.01% 1352

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Fieldpoint Private Securities's CTIC Position: Q4 2021 in Review

Fieldpoint Private Securities sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2021, closing a stake of 1,000 shares — an estimated $3K sold.

Fieldpoint Private Securities first reported a position in CTIC in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 63 funds tracked by Wall St. Rank hold CTIC as of Q4 2021.

  • Fieldpoint Private Securities reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2021 after selling out during the quarter.
  • Fieldpoint Private Securities sold 1,000 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2021, an estimated $3K.
  • Fieldpoint Private Securities first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2021 and held it in 3 quarters.
  • Fieldpoint Private Securities's CTI BioPharma Corp. (DE) Common Stock position peaked at $3K in Q3 2021.
  • 63 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2021.

Based on Fieldpoint Private Securities's 13F filing for Q4 2021, filed 24 Jan 2022.